|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SFTPD |
Gene summary for SFTPD |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SFTPD | Gene ID | 6441 |
| Gene name | surfactant protein D | |
| Gene Alias | COLEC7 | |
| Cytomap | 10q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | P35247 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6441 | SFTPD | TD9 | Human | Lung | IAC | 2.00e-06 | -9.80e-01 | 0.088 |
| 6441 | SFTPD | RNA-P10T2-P10T2-1 | Human | Lung | AAH | 2.17e-02 | -2.90e-01 | -0.1271 |
| 6441 | SFTPD | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 2.13e-02 | 1.29e-01 | -0.1408 |
| 6441 | SFTPD | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.33e-03 | -1.62e+00 | 0.3371 |
| 6441 | SFTPD | RNA-P17T-P17T-4 | Human | Lung | IAC | 5.99e-03 | -1.62e+00 | 0.343 |
| 6441 | SFTPD | RNA-P17T-P17T-6 | Human | Lung | IAC | 5.99e-03 | -1.62e+00 | 0.3385 |
| 6441 | SFTPD | RNA-P17T-P17T-8 | Human | Lung | IAC | 3.59e-04 | -1.62e+00 | 0.3329 |
| 6441 | SFTPD | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.20e-08 | 6.83e-02 | -0.2116 |
| 6441 | SFTPD | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 2.84e-10 | -1.30e-01 | -0.1941 |
| 6441 | SFTPD | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 1.62e-07 | -1.79e-03 | -0.2107 |
| 6441 | SFTPD | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 7.57e-05 | 1.10e-01 | -0.2119 |
| 6441 | SFTPD | RNA-P3T-P3T-1 | Human | Lung | IAC | 3.73e-16 | -1.48e+00 | 0.1829 |
| 6441 | SFTPD | RNA-P3T-P3T-2 | Human | Lung | IAC | 1.18e-18 | -1.60e+00 | 0.1835 |
| 6441 | SFTPD | RNA-P3T-P3T-3 | Human | Lung | IAC | 2.27e-05 | -1.62e+00 | 0.1745 |
| 6441 | SFTPD | RNA-P3T-P3T-4 | Human | Lung | IAC | 2.17e-17 | -1.62e+00 | 0.1859 |
| 6441 | SFTPD | RNA-P6T1-P6T1-1 | Human | Lung | MIAC | 2.22e-04 | -8.26e-01 | -0.0238 |
| 6441 | SFTPD | RNA-P6T1-P6T1-2 | Human | Lung | MIAC | 3.04e-05 | -9.94e-01 | -0.0186 |
| 6441 | SFTPD | RNA-P6T1-P6T1-3 | Human | Lung | MIAC | 7.36e-07 | -6.56e-01 | -0.0296 |
| 6441 | SFTPD | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 1.90e-08 | -8.74e-01 | -0.0263 |
| 6441 | SFTPD | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 5.25e-40 | -8.86e-01 | -0.0166 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0048875 | Lung | IAC | chemical homeostasis within a tissue | 11/2061 | 14/18723 | 7.44e-09 | 1.05e-06 | 11 |
| GO:0043129 | Lung | IAC | surfactant homeostasis | 10/2061 | 12/18723 | 1.37e-08 | 1.77e-06 | 10 |
| GO:00444038 | Lung | IAC | biological process involved in symbiotic interaction | 63/2061 | 290/18723 | 8.57e-08 | 8.34e-06 | 63 |
| GO:00068985 | Lung | IAC | receptor-mediated endocytosis | 50/2061 | 244/18723 | 1.01e-05 | 3.23e-04 | 50 |
| GO:00439038 | Lung | IAC | regulation of biological process involved in symbiotic interaction | 20/2061 | 72/18723 | 6.79e-05 | 1.45e-03 | 20 |
| GO:00224078 | Lung | IAC | regulation of cell-cell adhesion | 76/2061 | 448/18723 | 8.16e-05 | 1.68e-03 | 76 |
| GO:0007585 | Lung | IAC | respiratory gaseous exchange by respiratory system | 18/2061 | 68/18723 | 2.99e-04 | 4.82e-03 | 18 |
| GO:00421106 | Lung | IAC | T cell activation | 77/2061 | 487/18723 | 6.82e-04 | 9.20e-03 | 77 |
| GO:00071596 | Lung | IAC | leukocyte cell-cell adhesion | 60/2061 | 371/18723 | 1.47e-03 | 1.57e-02 | 60 |
| GO:00018947 | Lung | IAC | tissue homeostasis | 46/2061 | 268/18723 | 1.50e-03 | 1.60e-02 | 46 |
| GO:00508636 | Lung | IAC | regulation of T cell activation | 54/2061 | 329/18723 | 1.77e-03 | 1.82e-02 | 54 |
| GO:19030376 | Lung | IAC | regulation of leukocyte cell-cell adhesion | 54/2061 | 336/18723 | 2.82e-03 | 2.55e-02 | 54 |
| GO:00602497 | Lung | IAC | anatomical structure homeostasis | 51/2061 | 314/18723 | 2.91e-03 | 2.61e-02 | 51 |
| GO:00303243 | Lung | IAC | lung development | 32/2061 | 177/18723 | 3.26e-03 | 2.80e-02 | 32 |
| GO:00303233 | Lung | IAC | respiratory tube development | 32/2061 | 181/18723 | 4.63e-03 | 3.65e-02 | 32 |
| GO:00420986 | Lung | IAC | T cell proliferation | 34/2061 | 199/18723 | 6.20e-03 | 4.47e-02 | 34 |
| GO:004440313 | Lung | AIS | biological process involved in symbiotic interaction | 58/1849 | 290/18723 | 1.33e-07 | 1.44e-05 | 58 |
| GO:000689812 | Lung | AIS | receptor-mediated endocytosis | 50/1849 | 244/18723 | 4.47e-07 | 3.52e-05 | 50 |
| GO:00488751 | Lung | AIS | chemical homeostasis within a tissue | 9/1849 | 14/18723 | 1.11e-06 | 7.51e-05 | 9 |
| GO:00431291 | Lung | AIS | surfactant homeostasis | 8/1849 | 12/18723 | 3.07e-06 | 1.64e-04 | 8 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414516 | Lung | MIAC | Phagosome | 18/507 | 152/8465 | 4.17e-03 | 3.28e-02 | 2.37e-02 | 18 |
| hsa0414517 | Lung | MIAC | Phagosome | 18/507 | 152/8465 | 4.17e-03 | 3.28e-02 | 2.37e-02 | 18 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SFTPD | SNV | Missense_Mutation | c.539C>G | p.Thr180Arg | p.T180R | P35247 | protein_coding | tolerated(0.21) | benign(0.08) | TCGA-A8-A076-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| SFTPD | SNV | Missense_Mutation | c.186G>T | p.Glu62Asp | p.E62D | P35247 | protein_coding | deleterious(0.01) | possibly_damaging(0.876) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| SFTPD | SNV | Missense_Mutation | novel | c.509T>C | p.Val170Ala | p.V170A | P35247 | protein_coding | tolerated(1) | benign(0) | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
| SFTPD | SNV | Missense_Mutation | rs149865718 | c.178N>T | p.Arg60Trp | p.R60W | P35247 | protein_coding | tolerated(0.07) | benign(0.062) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SFTPD | SNV | Missense_Mutation | c.976N>C | p.Tyr326His | p.Y326H | P35247 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SFTPD | SNV | Missense_Mutation | c.798N>T | p.Lys266Asn | p.K266N | P35247 | protein_coding | deleterious(0.02) | probably_damaging(0.973) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SFTPD | SNV | Missense_Mutation | rs548930059 | c.913N>A | p.Val305Ile | p.V305I | P35247 | protein_coding | tolerated(0.2) | benign(0) | TCGA-AA-3842-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PD |
| SFTPD | SNV | Missense_Mutation | novel | c.545C>A | p.Ala182Glu | p.A182E | P35247 | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-AA-3867-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| SFTPD | SNV | Missense_Mutation | novel | c.871N>A | p.Pro291Thr | p.P291T | P35247 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| SFTPD | SNV | Missense_Mutation | novel | c.353N>A | p.Gly118Glu | p.G118E | P35247 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |